Loading in 2 Seconds...
Loading in 2 Seconds...
The latest market report published by Credence Research, Inc. “Global Glioblastoma Multiforme\nMarket- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 -\n2022,” the glioblastoma multiforme market was valued at USD 352.2 Mn in 2015
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
“Glioblastoma Multiforme Market- Growth, Share, Opportunities,
Competitive Analysis, and Forecast 2016 – 2023”
The latest market report published by Credence Research, Inc. “GlobalGlioblastoma Multiforme
Market- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 -
2022,” the glioblastoma multiforme market was valued at USD 352.2 Mn in 2015, and is expected to
reach USD 898.9 Mn by 2022, expanding at a CAGR of 10.95% from 2016 to 2022.
Browse the full report Glioblastoma Multiforme Market - Growth, Share, Opportunities,
Glioblastoma multiforme (GBM) belongs to a group of brain tumors known as gliomas that grows
from a type of brain cell called a glial cell. It is the most common primary brain tumor in adults and
also the most aggressive form of brain tumor. According to U.S. National Cancer Institute, GBM is
considered as the most aggressive form of brain cancer which represents 15.4% of all primary brain
tumors and about 60% - 75% of all astrocytoma and shows rapid growth rate of benign cells in the
organ. According to World Health Organization (WHO), the incidence of glioblastoma multiforme
(GBM) is 2 to 3 per 100,000 people in the United States and Europe. Overall GBM accounts for 12 to
15% of all intracranial tumors and 50 to 60% of astrocytic tumors. In year 2015, temozolomide
accounted for the largest market share of the global glioblastoma multiforme market. The key
advantages possessed by temozolomide are delayed progression without impacting the quality of life
and less adverse effects compared to other molecules. Medical practitioners suggest that,
combination radiotherapy and temozolomide chemotherapy is currently the standard of care for most
patients suffering from GBM. On the other hand, the geographical analysis of glioblastoma
multiforme market projected North America and Europe as the dominant regions followed by Asia-
Pacific. The key factors driving the glioblastoma multiforme market include developed research and
development facilities, upcoming drug launches, rising incidences of the central nervous system
cancers in the geriatric population. Thus, upcoming drugs and ongoing research developments are
expected to drive the overall market og glioblastoma multiforme market across the globe.
The phase III drugs included in the pipeline analysis are TRC-105, VB-111, TOCA 511, DCVax-Brain,
Rindopepimut (CDX-110), and others. According to market experts, these upcoming drugs assure to
provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the
currently available glioblastoma multiforme treatment. Large number of investigational molecules
belongs to immunotherapy category which is expected to change the overall perspective of the
market. Thus, future commercialization of these molecules during the forecast period 2016 – 2022 is
anticipated to have a reflective impact on the growth of the overall glioblastoma multiforme market.
Browse the full Glioblastoma Multiforme Market - Growth, Future Prospects and Competitive Analysis,
2017 – 2025 report at http://www.credenceresearch.com/report/glioblastoma-multiforme-market
Credence Research is a worldwide market research and counseling firm that serves driving organizations,
governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with
making enduring enhancements to their execution and understand their most imperative objectives. Over almost
a century, we've manufactured a firm extraordinarily prepared for this task.
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US